Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis
References (37)
- et al.
Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons
European J. Pharmacol.
(1971) - et al.
Stereoselectivity of presynaptic autoreceptors modulating dopamine release
European J. Pharmacol.
(1981) Presynaptic regulation of neurotransmitter release in the brain
Neuroscience
(1984)- et al.
Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate-cyclase by kainic acid
Brain Res.
(1977) - et al.
The dopamine autoreceptor agonist BHT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment
European J. Pharmacol.
(1986) SCH 23390: the first selective dopamine D-1 antagonist
European J. Pharmacol.
(1983)- et al.
The D-1 antagonist SCH 23390 stimulates while D-1 agonist SKF 38393 fails to affect dopamine release in the dorsal caudate of freely moving rats
European J. Pharmacol.
(1987) - et al.
Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions in the striatum
Brain Res.
(1980) - et al.
(−)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanaesthetized rats
Brain Res.
(1983) - et al.
6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors
European J. Pharmacol.
(1987)
The central effects of a novel dopamine agonist
European J. Pharmacol.
Two dopamine receptors: biochemistry, physiology and pharmacology
Life Sci.
Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis
European J. Pharmacol.
Dopamine's autoreceptors: Pharmacological characterization by microiontophoretic single cell recording studies
Naunyn-Schmiedeb. Arch. Pharmacol.
Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs
J. Pharmacol.
Selective stimulation of dopamine and noradrenaline autoreceptors by BHT 933, respectively
Naunyn-Schmiedeb. Arch. Pharmacol.
Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fiber through the dorsal hippocampus in the rat
J. Neurochem.
Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity
J. Pharmacol. Exp. Ther.
Cited by (124)
Immunolocalization of kappa opioid receptors in the axon initial segment of a group of embryonic mesencephalic dopamine neurons
2022, IBRO Neuroscience ReportsCitation Excerpt :In the NAc, D2R are pre-synaptically localized on axon terminals and post-synaptically on dendrites of MSN GABA neurons (Pickel et al., 2006). Activation of D2R within the NAc decreases dopamine extracellular levels (Imperato and Di Chiara, 1988). Likewise, KORs are abundant in the mesolimbic system (Mansour et al., 1996) and negatively control dopamine neurotransmission.
Behavioral sensitization to ethanol: Neural basis and factors that influence its acquisition and expression
2016, Brain Research BulletinRegulation of Extracellular Dopamine: Release and Uptake
2016, Handbook of Behavioral NeuroscienceData collection and analysis strategies for phMRI
2014, NeuropharmacologyHistamine H<inf>3</inf> receptor activation prevents dopamine D<inf>1</inf> receptor-mediated inhibition of dopamine release in the rat striatum: A microdialysis study
2013, Neuroscience LettersCitation Excerpt :To confirm the effects of D1R activation on striatal DA release, 2 groups of rats (n = 3 per group) received an intra-striatal application of the D1R agonist SKF-38393 (0.5 or 1 μM). The concentrations of SKF-38393 were based on previous studies [16,29,42]. The role of D1Rs and H3Rs in striatal DA release was studied in 18 rats, which were separated into 3 groups: (a) intrastriatal application of the D1R agonist SKF-38393 (0.5 μM, n = 6); (b) co-administration of SKF-38393 and the H3R agonist immepip (10 μM, n = 6); and (c) co-administration of SKF-38393, immepip and the H3R antagonist thioperamide (10 μM).